^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    KUR-502

    i
    Other names: KUR-502, KUR-502 CAR-NKT Therapy, CD19.CAR-aNKT cells, CD19.CAR Allogeneic NKT, CMD-502, KUR502, KUR 502
    Associations

    News

    Trials
    Company:
    Athenex, Baylor College of Medicine, Texas Children’s Hospital
    Drug class:
    CD19-targeted CAR-T immunotherapy
    Related drugs:
    Associations

    News

    Trials
    5ms
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Baylor College of Medicine | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • KUR-502
    5ms
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Baylor College of Medicine | Trial completion date: Feb 2034 --> Feb 2035
    Trial completion date
    |
    CD19 positive
    |
    cyclophosphamide • KUR-502
    6ms
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=13, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=48 --> 13 | Trial completion date: Mar 2035 --> Feb 2034 | Trial primary completion date: Jan 2026 --> May 2025
    Enrollment closed • Enrollment change • Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • KUR-502
    over1year
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2025 --> Jan 2026
    Trial primary completion date
    |
    cyclophosphamide • KUR-502
    over1year
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2024 --> Apr 2025
    Trial primary completion date
    |
    cyclophosphamide • KUR-502
    over2years
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=48, Recruiting, Baylor College of Medicine | Trial primary completion date: Apr 2023 --> Apr 2024
    Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • KUR-502
    3years
    ANCHOR2: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (clinicaltrials.gov)
    P1, N=36, Recruiting, Athenex, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • KUR-502
    over3years
    ANCHOR2: Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies (clinicaltrials.gov)
    P1, N=36, Not yet recruiting, Athenex, Inc.
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • KUR-502
    5years
    CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR) (clinicaltrials.gov)
    P1, N=48, Recruiting, Baylor College of Medicine | N=20 --> 48
    Clinical • Enrollment change
    |
    CD19 (CD19 Molecule)
    |
    CD19 positive
    |
    fludarabine IV • KUR-502 • cyclophosphamide intravenous